$HROW News

BTIG Reiterates Buy on Harrow, Maintains $63 Price Target

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To Lucentis

Harrow Presents Three Studies Supporting IHEEZO, Low Viscosity Ocular Anesthetic Gel, And BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTIS At ASRS 2026 Annual Meeting

Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis

GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1

Is Harrow, Inc. (HROW) A Good Stock To Buy Now?

Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow Re-Launches Steroid-Sparing VERKAZIA For Vernal Keratoconjunctivitis, Targeting Underlying Inflammatory Mechanisms In Pediatric Patients

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism

Harrow Inc (NASDAQ:HROW): An Affordable Growth Play Combining Rapid Expansion with Reasonable Valuation

Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold

Harrow, Inc. 2026 Q1 - Results - Earnings Call Presentation

Mark Baum Buys Handful Of Shares In Harrow